Autologous stem cell therapy - OmniCyte
Latest Information Update: 13 Aug 2015
At a glance
- Originator OmniCyte Ltd
- Class Cardiovascular therapies; Stem cell therapies
- Mechanism of Action Tissue replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Liver disorders
Most Recent Events
- 26 Mar 2006 Phase-II clinical trials in Liver disorders in United Kingdom (unspecified route)